It's something I've written about a few times now, BREXIT and the uncertainties that surround it all for our Pharma/Healthcare industry.

Surely there is one common goal at the end of all this and that is that patients aren't affected negatively. Whether that be UK nationals no longer being able to access healthcare aboard - or vice versa. Or, if we can no longer collaborate in major medical studies, getting left behind our peers across the continent.

Thankfully, the Alliance has outlined this as being one of the key five areas of priority for the BREXIT negotiations...